World Conference on Lung Cancer

Jorge Nieva, MD, discusses how long-term responses in ROS1+ non–small cell lung cancer affect imaging frequency, MRD testing, and treatment intensification.

Jorge Nieva, MD, reviews long-term taletrectinib data in ROS1+ non–small cell lung cancer, including about 90% response rates across fusion partners and manageable safety.

David R. Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.

The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.

KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.

The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.

Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.

Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.

First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.

The B7-H3–directed antibody-drug conjugate risvutatug rezetecan improved overall survival in the China-based ARTEMIS-008 study of relapsed extensive-stage small cell lung cancer presented at WCLC.

ARROS-1 data show zidesamtinib drives 94% responses in untreated ROS1+ NSCLC, including brain metastases, supporting first-line FDA filing.

Ivonescimab extends survival and doubles PFS vs pembrolizumab in first-line PD‑L1+ metastatic NSCLC, with manageable safety.

New trial data shows ivonescimab combined with chemotherapy significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer patients.

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Tarlatamab-dlle combined with anti-PD-L1 therapy shows remarkable survival rates and manageable safety in extensive-stage small cell lung cancer patients.

SHR-4849 shows promising efficacy and manageable safety in relapsed small cell lung cancer, highlighting its potential as a targeted treatment option.

New findings reveal zongertinib's effectiveness against brain metastases in HER2-mutant non–small cell lung cancer, offering hope for better treatment options.

New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.

A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion–mutated NSCLC, offering hope for patients.

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.

Firmonertinib shows significant antitumor activity in EGFR PACC-mutated NSCLC, with promising results in CNS penetration and manageable safety profiles.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.